Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in ...

Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter sales report. That ...

The US President announced a list of updates concerning US trade tariffs on Tuesday, including a deal with Indonesia and his ...

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Trump’s latest two industrial sector tariffs—200 percent on pharmaceuticals and 50 percent on copper—have serious ...

Pharmaceutical air logistics is undergoing a structural transformation, as mergers, infrastructure investments, and real-time ...

Kairos Pharma shares were higher as the company reported positive safety results from a clinical trial of ENV-105, or carotuximab, in patients with metastatic castration-resistant prostate cancer.

Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progressTotal addressable market (TAM) for ARAKODA for Human Babesiosis is ...

PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded ...

Merck & Co., Inc. is acquiring Verona Pharma plc for $10bn to bolster long-term growth with COPD drug Ohtuvayre. Click for my ...